BRAF and neoplasm: Such comparator datasets will also provide information on the impact of novel targeted therapies (BRAF and MEK inhibitors) on similar tumour control, neuroendocrine, and neurobehavioural outcomes in this vulnerable group and require intensive collaborative efforts.